Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

MAVORIC Investigators

Research output: Contribution to journalArticlepeer-review

110 Scopus citations

Fingerprint Dive into the research topics of 'Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences